BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 21757451)

  • 1. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease.
    Cullen G; Bader C; Korzenik JR; Sands BE
    Gut; 2012 Mar; 61(3):385-91. PubMed ID: 21757451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease.
    Mamula P; Markowitz JE; Piccoli DA; Klimov A; Cohen L; Baldassano RN
    Clin Gastroenterol Hepatol; 2007 Jul; 5(7):851-6. PubMed ID: 17544875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
    Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice.
    Ribeiro AC; Guedes LK; Moraes JC; Saad CG; Aikawa NE; Calich AL; França IL; Carvalho JF; Sampaio-Barros PD; Goncalves CR; Borba EF; Timenetsky Mdo C; Precioso AR; Duarte A; Bonfa E; Laurindo IM
    Ann Rheum Dis; 2011 Dec; 70(12):2144-7. PubMed ID: 21859696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective Study.
    Launay O; Abitbol V; Krivine A; Slama LB; Bourreille A; Dupas JL; Hébuterne X; Savoye G; Deplanque D; Bouhnik Y; Pelletier AL; Galtier F; Laharie D; Nachury M; Zerbib F; Allez M; Bommelaer G; Duclos B; Lucht F; Gougeon ML; Tartour E; Rozenberg F; Hanslik T; Beaugerie L; Carrat F;
    J Crohns Colitis; 2015 Dec; 9(12):1096-107. PubMed ID: 26351392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients.
    Lertdumrongluk P; Changsirikulchai S; Limkunakul C; Prachukthum P; Punpiput P; Buppanharun R; Chotpitayasunondh C
    Vaccine; 2012 Feb; 30(6):1108-14. PubMed ID: 22178515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial.
    Le Corre N; Thibault F; Pouteil Noble C; Meiffrédy V; Daoud S; Cahen R; Charreau I; Bottigioli D; Dollinger C; Aboulker JP; Autran B; Morelon E; Barrou B
    Vaccine; 2012 Dec; 30(52):7522-8. PubMed ID: 23103195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
    Lagler H; Wenisch JM; Tobudic S; Gualdoni GA; Rödler S; Rasoul-Rockenschaub S; Jaksch P; Redlberger-Fritz M; Popow-Kraupp T; Burgmann H
    Vaccine; 2011 Sep; 29(40):6888-93. PubMed ID: 21803100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effect of A/H1N1 vaccination in immune-mediated disease--a prospectively controlled vaccination study.
    Adler S; Krivine A; Weix J; Rozenberg F; Launay O; Huesler J; Guillevin L; Villiger PM
    Rheumatology (Oxford); 2012 Apr; 51(4):695-700. PubMed ID: 22171015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus.
    Mathian A; Devilliers H; Krivine A; Costedoat-Chalumeau N; Haroche J; Huong DB; Wechsler B; Hervier B; Miyara M; Morel N; Le Corre N; Arnaud L; Piette JC; Musset L; Autran B; Rozenberg F; Amoura Z
    Arthritis Rheum; 2011 Nov; 63(11):3502-11. PubMed ID: 21811996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situation.
    Lagler H; Tobudic S; Ramharter M; Elandt K; Sperr WR; Redlberger-Fritz M; Popow-Kraupp T; Jäger U; Zielinski CC; Burgmann H
    Vaccine; 2012 Nov; 30(48):6864-70. PubMed ID: 22989690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved serological response to H1N1 monovalent vaccine associated with viral suppression among HIV-1-infected patients during the 2009 influenza (H1N1) pandemic in the Southern Hemisphere.
    Maruszak H; Jeganathan S; Smith DE; Robertson P; Barnes T; Furner V
    HIV Med; 2012 Jul; 13(6):352-7. PubMed ID: 22296264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients.
    Fairhead T; Hendren E; Tinckam K; Rose C; Sherlock CH; Shi L; Crowcroft NS; Gubbay JB; Landsberg D; Knoll G; Gill J; Kumar D
    Transpl Infect Dis; 2012 Dec; 14(6):575-83. PubMed ID: 22999005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus.
    Campos LM; Silva CA; Aikawa NE; Jesus AA; Moraes JC; Miraglia J; Ishida MA; Bueno C; Pereira RM; Bonfa E
    Arthritis Care Res (Hoboken); 2013 Jul; 65(7):1121-7. PubMed ID: 23818263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diminished immunogenicity to pandemic H1N1 2009 influenza vaccine in subjects with severe motor and intellectual disability.
    Hara M; Hanaoka T; Mizushima T; Honma J; Maeda K; Ohfuji S; Tanaka K; Hirota Y
    Vaccine; 2011 Oct; 29(46):8323-9. PubMed ID: 21893146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
    Pariani E; Boschini A; Amendola A; Poletti R; Anselmi G; Begnini M; Ranghiero A; Cecconi G; Zanetti AR
    Vaccine; 2011 Nov; 29(49):9209-13. PubMed ID: 21974995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term patterns of humoral and cellular response after vaccination against influenza A (H1N1) in patients with hematologic malignancies.
    Mariotti J; Spina F; Carniti C; Anselmi G; Lucini D; Vendramin A; Pregliasco F; Corradini P
    Eur J Haematol; 2012 Aug; 89(2):111-9. PubMed ID: 22540245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A survey of levels of antibodies against influenza viruses in the population of Wuxi City].
    You FX; Sun N; Ma GY; Wang MM; Sa D; Shi C; Wu JL; Lin X; Xiao Y; Qian YH; Jiang Y; Xie J; Ji YY; Guan HX
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Oct; 25(5):351-4. PubMed ID: 22338222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
    Dong PM; Li YQ; Zheng TZ; Jia YP; Li F; Han TW; Qiao RX; Zhang BH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy.
    Rahier JF; Papay P; Salleron J; Sebastian S; Marzo M; Peyrin-Biroulet L; Garcia-Sanchez V; Fries W; van Asseldonk DP; Farkas K; de Boer NK; Sipponen T; Ellul P; Louis E; Peake ST; Kopylov U; Maul J; Makhoul B; Fiorino G; Yazdanpanah Y; Chaparro M;
    Gut; 2011 Apr; 60(4):456-62. PubMed ID: 21270121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.